4 Health Services Stocks Pushing The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 15,098 as of Friday, Aug. 16, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,393 issues advancing vs. 1,555 declining with 92 unchanged.

The Health Services industry currently sits down 0.6% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Parexel International Corporation ( PRXL), up 2.7%, Boston Scientific ( BSX), up 1.6%, Cigna ( CI), up 1.4% and Aetna ( AET), up 0.9%. On the negative front, top decliners within the industry include Edwards Life ( EW), down 2.0%, CareFusion ( CFN), down 1.1%, St Jude Medical ( STJ), down 1.1%, DaVita HealthCare Partners ( DVA), down 1.0% and Waters Corporation ( WAT), down 1.0%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $0.40 (1.3%) to $31.95 on average volume. Thus far, 182,648 shares of Grifols exchanged hands as compared to its average daily volume of 461,000 shares. The stock has ranged in price between $31.14-$31.96 after having opened the day at $31.60 as compared to the previous trading day's close of $31.55.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $10.8 billion and is part of the health care sector. Shares are up 21.4% year to date as of the close of trading on Thursday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, ResMed ( RMD) is up $0.89 (1.8%) to $49.37 on light volume. Thus far, 303,784 shares of ResMed exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $48.70-$49.38 after having opened the day at $48.91 as compared to the previous trading day's close of $48.48.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $7.0 billion and is part of the health care sector. Shares are up 17.2% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate ResMed a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full ResMed Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, WellPoint ( WLP) is up $1.11 (1.3%) to $86.53 on average volume. Thus far, 820,037 shares of WellPoint exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $85.13-$86.77 after having opened the day at $85.15 as compared to the previous trading day's close of $85.42.

WellPoint, Inc., a health benefits company, through its subsidiaries, offers network-based managed care plans to large and small employer, individual, Medicaid, and senior markets in the United States. The company operates through three segments: Commercial, Consumer, and Other. WellPoint has a market cap of $25.9 billion and is part of the health care sector. Shares are up 40.2% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate WellPoint a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates WellPoint as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full WellPoint Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Express Scripts ( ESRX) is up $0.66 (1.0%) to $64.63 on average volume. Thus far, 2.0 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $63.70-$64.76 after having opened the day at $63.92 as compared to the previous trading day's close of $63.97.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $53.7 billion and is part of the health care sector. Shares are up 21.2% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Express Scripts Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs